Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT 868

Next Previous
X
Search
Drug Profile

CT 868

Alternative Names: CT-868; GLP-1/GIP receptor agonist - Carmot Therapeutics; RG-6641

Latest Information Update: 13 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Carmot Therapeutics
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides; Small molecules
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 09 May 2024 Roche announces intention to submit regulatory application for Type 1 diabetes mellitus in or after 2027 (Roche pipeline, May 2024)
  • 29 Jan 2024 Carmot Therapeutics has been acquired by Roche
  • 15 Nov 2023 Efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus released by Carmot Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top